Saturable P-glycoprotein kinetics assayed by fluorescence studies of drug efflux from suspended human KB 8-5 cells  by Ghauharali, Rick I et al.
ELSEVIER Biochimica et Biophysica Acta 1278 (1996) 213 -222 
BB 
Bioc h if ic~a et Biophysica Acta 
Saturable P-glycoprotein kinetics assayed by fluorescence studies of 
drug effiux from suspended human KB8-5 cells 
Rick I. Ghauharali a, Hans V. Westerhoff  b,c, Henk Dekker a, Jan Lankelma a,* 
" Department of Medical Oncology, Free University Hospital, Room BR 232, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands 
b E.C. Slater Institute for Biochemical Research, BioCentrum, University of Amsterdam, Amsterdam, The Netherlands 
c The Netherlands Cancer Institute, Division of Molecular Biology, Amsterdam, The Netherlands 
Received 12 May 1995; revised 11 August 1995; accepted 19 September 1995 
Abstract 
This article describes a new and rapid method to determine the pumping rate of P-glycoprotein (P-gp) in intact cells. Multidrug 
resistant (MDR) human epidermoid carcinoma KB8-5 cells (containing P-gp) were loaded with daunorubicin (DNR) in the absence or in 
the presence of verapamil, sufficient o inhibit DNR pumping by P-gp. In either case, the cells were resuspended in medium devoid of 
DNR and the subsequent increase of the DNR fluorescence intensity was measured as a function of time. For cells loaded with the same 
amount of drug, the free cytosolic drug concentration (Ci(t)) was a unique function of the DNR medium concentration (Co(t)). The 
cellular drug content in the presence of verapamil decreased nonlinearly with decreasing extracellular drug concentration, i dicating that 
the intracellular drug apparent distribution volume increased with decreasing cellular drug content. At each fluorescence intensity, we 
calculated the P-gp mediated (verapamil-inhibitable) DNR transport rate from the rate of increase of the DNR fluorescence intensity in 
the absence of verapamil minus the rate of increase of the DNR fluorescence intensity in the presence of verapamil. When plotted against 
the intracellular free drug concentration (as calculated from the total cellular drug content and a separately determined relation between 
the total cellular drug content and the intracellular free drug concentration: the apparent distribution volume), this P-gp mediated DNR 
transport rate showed saturation of P-gp at higher DNR concentrations. The results imply that P-gp mediated DNR transport is saturable 
(the value of K M is in the order of I /xM). 
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1. Introduction 
P-glycoprotein (P-gp) can protect cells against lipophilic 
toxic compounds, among which are cytotoxic drugs [ 1-4]. 
Strong evidence has been obtained for an active transport 
process for these compounds across the plasma membrane 
of P-gp containing cells [5,6]. Total cellular drug uptake is 
affected by additional processes, such as passive drug leak 
across the plasma membrane [7,8], uptake by cellular 
organelles [9-12] and binding to macromolecules [ 13]. To 
understand the effect of P-gp on drug resistance and its 
reversal by modifiers, such as verapamil [14], the depen- 
dence of drug uptake on the kinetic and thermodynamic 
properties of all these processes hould be dissected. 
Abbreviations: MDR, multidrug-resistant/resistance; P-gp, P-glyco- 
protein; DNR, daunorubicin; Hepes, N-(2-hydroxyethyl)piperazine-N'-2- 
ethane sulfonic acid. 
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One important determinant of drug uptake into mul- 
tidrug resistant (MDR) cells is P-gp itself. A number of 
studies have zoomed in on the kinetics of drug pumping by 
this protein [8,15-18]. Of these, the studies in which P-gp 
functions in intact cells are of great interest. Such studies 
however, have to deal with the complication that the 
intracellular free drug concentration cannot be assessed nor 
controlled directly. Spoelstra et al. [8] estimated the intra- 
cellular free daunorubicin (DNR) concentration from the 
passive leak rate and a predetermined passive permeation 
coefficient. The variation of the P-gp pump rate, as mea- 
sured in a flow-through system at various concentrations 
of extracellular DNR, combined with the calculated intra- 
cellular free drug concentration, suggested that P-gp has 
saturable kinetics in terms of the estimated intracellular 
free DNR concentrations. 
Substrate saturability has the implication that at high 
substrate concentrations, the pump should function com- 
paratively ineffectively. Also the half-life of drug efflux 
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into drug free medium should decrease with time. It is this 
latter implication that is tested in this paper and then used 
to assess the kinetic properties of the drug efflux pump in 
a new manner. Drug efflux is followed in time in a 
spectrofluorometer. We show how both the pumping rate 
and the intracellular substrate concentration are calculated 
by computerized fluorometry and data processing. 
2. Materials and methods 
2.1. Cell culture 
The human epidermoid carcinoma cell line KB8-5 [19], 
selected by exposure to increasing concentrations of 
colchicine, was obtained from the American Type Culture 
Collection (Rockville, MD, USA). Cells were grown in 
monolayer in Nunc flasks (Roskilde, Denmark) in (bi- 
carbonate-buffered) Dulbecco's modified Eagle's medium 
(Flow Laboratories, Irvine, UK), supplemented with 20 
mM Hepes (Serva, Heidelberg, Germany) and 10% heat- 
inactivated fetal calf serum (FCS) (Gibco, Paisley, UK) 
under an atmosphere containing 5-6% CO 2 at 37°C. The 
cells were cultured with a selecting drug (25 nM colchicine) 
as described [19] until 2 to 7 days before experiments and 
were free of Mycoplasma, as tested with the Mycoplasma 
T.C. kit (Genprobe, San Diego, CA, USA). The DNR 
concentration needed to kill 50% of the cells was 50 nM at 
continuous presence in the medium for three to four days. 
At the conditions used for the effiux experiments in this 
paper, the viability as measured with Trypan blue was 
> 95%. 
2.2. Drug efflux measurements 
For DNR efflux measurements, exponentially growing 
cells were trypsinized and kept in suspension in a growth 
medium referred to as medium A, supplemented with 5% 
FCS. Medium A is based on phosphate buffered saline 
(PBS) Dulbecco's formula (modified) (Flow Laboratories) 
to which amino acids for minimum essential medium 
Eagle (modified) (Flow Laboratories), Hepes (20 mM), 
glucose (1 g l - l ,  Baker, Deventer, The Netherlands) and 
L-glutamine (4 raM, ICN Biochemicals, Cleveland, OH, 
USA) are added. The pH is adjusted to 7.4. 
Cells were loaded in this medium with DNR for 30 min 
at 37°C in the absence and in the presence of 50 /zM 
verapamil to inhibit DNR efflux by P-gp (in accordance 
with common practice, the rate of drug export is called 
'drug efflux'). In one set of experiments, the DNR concen- 
trations in the absence and presence of verapamil were 15 
/xM and 3 /zM, respectively. In another set of experiments 
these concentrations were 25 p~M and 15 /zM. These 
specific concentrations were chosen to result in loading 
with the same amount of DNR in the plus and minus 
verapamil case. After two washing steps with DNR free 
medium (at room temperature) ither 1-105 or 2-105 
cells (as determined with a hemocytometer) were sus- 
pended in 200 /zl of DNR-free medium. This suspension 
was then transferred to a quartz cuvette (QS, 10.00 mm 
path length) containing 2.5 ml of DNR-free medium at 
37°C. In the minus verapamil experiments, both the wash- 
ing medium and the efflux medium were verapamil free. In 
the plus verapamil experiments, these media were supple- 
mented with 50 /zM verapamil. 
During incubation, DNR is intercalated in DNA, lead- 
ing to a quenching of the DNR fluorescence intensity. 
During drug efflux, DNR is released from DNA, leading to 
an increase in the DNR fluorescence intensity, relative to 
the start of efflux. This increase of the DNR fluorescence 
intensity was monitored using a spectrofluorometer (SPEX 
Industries Inc., Model FluoroMax TM, Edison, NJ, USA) 
equipped with a Xenon lamp and a thermostatted cuvette- 
chamber. Excitation was at 480 nm, emission was detected 
at 590 nm, through a 1 mm slit for both excitation and 
emission. The cell suspension was stirred continuously 
using a cell spinbar ® (Bel-Art Products, Pequannock, NJ, 
USA) and the temperature of the cuvette was kept at 37°C. 
During both incubation with DNR, washing and DNR 
efflux, methylamine (10 mM) was present in the medium 
to decrease the effects of DNR entrapped in acidic intra- 
cellular compartments. At the end of the experiment digi- 
tonin was added for plasma membrane permeabilization 
(total concentration 30 /xM). 
The relationship between total cellular drug content and 
intracellular f ee drug concentration, the apparent distribu- 
tion volume, was determined by exposing cells at low cell 
density and at high verapamil concentration to various 
drug concentrations for at least 30 min and measuring 
(after washing) how much (radiolabelled) rug had accu- 
mulated in the cells (Qi below). 
2.3. Chemicals 
Daunorubicin hydrochloride was obtained from Specia 
(Pads, France). Verapamil, methylamine and digitonin 
(50% pure) were from Sigma (St. Louis, MO, USA). 
2.4. Data processing 
2.4.1. Mathematical nalysis 
For the analysis of DNR transport across the plasma 
membrane, we assume a three compartment model. Two 
compartments are the extracellular medium and a cellular 
space (e.g., cytosol) with equal fluorescence quantum yields 
for DNR. It is assumed that P-gp pumps between these 
compartments. The third compartment is assumed to equi- 
librate with the second compartment in terms of the DNR 
activity but quenches the DNR fluorescence intensity. This 
assumption was valid because the time constant of drug 
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release from the fluorescence intensity quenching sites was 
smaller than the time constant of drug release into the 
extracellular medium (see also the Results section). The 
most likely cause for quenching of cellular DNR is interca- 
lation in nuclear DNA [13,20,21]. The third compartment 
is mostly nuclear DNA. DNR transport across the plasma 
membrane will be described as the sum of a passive 
component (diffusion) and an active component (P-gp 
mediated transport). 
In appendix A we show how to calculate the free drug 
concentration difference across the plasma membrane as a 
function of time and the active (P-gp mediated) transport 
rate as a function of the free drug concentration difference 
across the plasma membrane from experimental data. Then 
the intracellular free drug concentration as a function of 
time is calculated from the total cellular DNR content 
(which is calculated from experimental data) and an exper- 
imentally determined relation between in the total cellular 
DNR content and the intracellular f ee drug concentration. 
Combination of these results yields the active transport 
rate as a function of the intracellular free drug concentra- 
tion. In this section, we summarize the results and refer to 
appendix A for a detailed analysis. 
The free drug concentration difference across the plasma 
membrane can be written as: 
c , ( t )  - Co(t )  
= Feq-F'+vp(t)  8Vtot(Ci(t)) 
1 - q_+ vp VoutVcells(Ci(t)) 
8Fl ( gcells(fi,eq) gtot(Ci(t)) ) 
+ Vout Vcells(Ci(t) ) Vtot(Ci,eq ) 1 (1) 
in which Ci(t) (tool 1-1) and Co(t) (mol 1-1) are the 
intracellular and extracellular free DNR concentrations, 
respectively. F+ vp(t) (counts per s, cps) is the detected 
DNR fluorescence intensity as a function of time in the 
absence or presence of verapamil (representing both the 
medium fluorescence intensity and the cellular DNR fluo- 
rescence intensity), Feq (cps) is the DNR fluorescence 
intensity after membrane permeabilization and equilibra- 
tion of DNR across the plasma membrane and q,+ Vp is the 
so-called quenching factor, defined as the ratio of the 
cellular DNR fluorescence intensity at the start of efflux 
(referred to as F_+ vp(t = 0) (cps)) and the DNR fluores- 
cence intensity that would be obtained if all the DNR were 
free in the extracellular solution after efflux and no cellular 
DNR quenching would occur (referred to as F 1 (cps)). Vou t
(1) and Wcells(Ci(t)) (1) represent the extracellular and the 
apparent distribution volume for DNR of the cells, respec- 
tively. The apparent otal volume, Vtot(Ci(C)) (1), is de- 
fined as the sum of the former and e (mol cps -1) is a 
constant relating the medium DNR fluorescence intensity 
to the amount of DNR in the medium. 
Vcells ( Ci ) 
and 
The active DNR transport rate, Jp (mol s -1 (10 6 
cells)-1), can be written as: 
Jp = J-vp - J+vp (2) 
in which J+vp (mol s -1 (10 6 cells) - j )  represents the 
transport rate in the absence or presence of verapamil, 
which is related to the measured DNR fluorescence inten- 
sity through: 
g d 
J+vp(Ci(t),Co(t)) 1 - q+-vp di(F+_vp(t))  (3) 
Eqs. (1), (2) and (3) yield Jp as a function of the free drug 
concentration difference across the plasma membrane. 
The variation of the amount of intracellular drug with 
time can be obtained from: 
F~q - F+ Vp(t) 
Qi(t) = e (4a) 
1 - q+vp 
The intracellular free drug concentration at time t is 
related to the total cellular drug content, Qi(t). To the 
extent hat the binding constant of the drug to DNA varies 
with the intracellular drug concentration, Vcells(Ci) var ies  
with C i. We assume that the dependence of Vce.~(C i) on C i 
is the same for the experiments in the presence and 
absence of verapamil. Vce.s(C i) was measured by titrating 
with DNR and measuring the cellular DNR accumulation 
in the presence of verapamil (at which the pumping of 
DNR was inhibited) and at equilibrium (when the intra- 
cellular free drug concentration equalled the extracellular 
free drug concentration). 
Qi 
Ci ,+ vp (4b) 
Qi(t) 
ci(t)  Vce n., ( Ci ) (4c) 
2.5. Numerical analysis 
The effiux curves were numerically processed in pairs 
(plus-and minus-verapamil) in seven steps. Discriminating 
between F+ vp(t) curves (fluorescence intensity as a func- 
tion of (e(flux) time) and /~(AF)+v p curves (rate of 
increase of the fluorescence intensity as a function of the 
fluorescence intensity difference Feq - F+ vp(t)) the proce- 
dure was as follows: 
2.5.1. F +_ Vp(t) based calculations: 
(1) Calculation of the curve  Feq - F+ vp(t) as a function 
of time, followed by noise reduction with a nine-point 
moving average filter 
(2) Data compression by discarding eight of every nine 
points in the filtered data set 
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(3) Calculation of the difference quotient, representing 
the drug efflux rate 
A( Feq - F + vp(t) ) 
At 
(Feq -- F+ Vp( ti+ ] ) )  - - (  Feq-  F+ vp(ti)) 
ti+ 1 -- ti 
( r+ vp( ti+ l ) - F+ Vp(ti)) (5) 1 
ti+ 1 -- ti 
as a function of (Feq - F+ vv(t))/(1 - q+ vp) 
2.5.2. F(AF)+ Vp based calculations: 
(4) Interpolation of the plus-verapamil curve with a fifth 
order polynomial and calculation of the drug efflux rate of 
the plus-verapamil curve at (Feq-  F_vp( t ) ) / (1 -  q-vp)  
values of the minus-verapamil curve 
(5) Calculation of the difference curve: drug efflux rate 
in the minus-verapamil case minus drug efflux rate in the 
of (Feq-  plus-verapamil case at equal magnitude 
F-vp(t))/(1 - q- Vp) 
(6) Calibration of the y-axis using: 
d(Feq-F(t )+vp ) d(F+ vp(t)) 
dt dt 
(1 -q±vp)  d(Qo(t)) 
dt 
_ (1 -q+vp)  d(Qi(t)) (6) 
dt 
7. Calibration of the x-axis of the difference curve 
using Eq. (4). 
3. Results 
3.1. The fluorescence signal during DNR effiux 
Fig. 1 represents he increase of the DNR fluorescence 
intensity during efflux from KB8-5 cells in the presence 
(dotted line) and in the absence (solid line) of verapamil n 
a representative experiment. The first 64 s represent the 
baseline: the emission intensity of cuvette and drug free 
efflux medium. At t = 64 s the incubated cell suspension 
is transferred to the cuvette. The immediate increase in the 
fluorescence intensity represents he sum of cellular auto- 
fluorescence and scattering (minor contribution) and cellu- 
lar DNR fluorescence (major contribution). As DNR was 
released from DNA during efflux, a gradual increase of the 
DNR fluorescence intensity was observed. At the end of 
the experiment, digitonin was added for plasma membrane 
permeabilization. From the subsequent rapid rise of the 
fluorescence intensity, it was concluded that equilibration 
with intracellular binding was relatively quick. Addition of 
digitonin in earlier phases of the experiment also showed a 
relatively rapid increase of the signal (data not shown), 
indicating that also in phases of more rapid change, the 
plasma membrane permeability controlled DNR efflux. For 
the plus-verapamil case, the addition of digitonin hardly 
affected the fluorescence intensity after efflux of DNR, 
confirming that Vcells(Ci(t))/Vtot(Ci(t)) was negligible. 
3.2. Determination of the cellular quenching factor q +_ vp 
Titration with DNA of a solution containing 1 /xM 
DNR resulted in a quenching of the DNR fluorescence 
intensity, down to 5% of the initial value, in agreement 
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Fig. l. Fluorescence signal (excitation and emission wavelengths 480 and 590 nm, respectively) of daunorubicin during efflux from human multidrug 
resistant KB8-5 cells in the absence (solid line) and in the presence (dashed line) of 50 /xM verapamil. Before effiux, the cells were loaded for 30 min at 
37°C in presence and in absence of verapamil with 15 /zM and 25 /.tM daunorubicin, respectively. At the end of the experiment, digitonin was added for 
plasma membrane permeabilization (total concentration 30 p,M). The cell density was 3.7 • l0 n cells mV ~. 
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Fig. 2. The slopes of three plus-verapamil curves representing the drug 
efflux rate of three different experiments plotted against the normalized 
(Feq - F+ vp(t))/(l - q+ vp) using q+ vp = 0.19. Experimental parame- 
ters: DNR incubation concentration: 15 /zM, cell density: 3.7. l04 cells 
ml -I (squares), DNR incubation concentration: 15p.M, cell density: 
7.4.104 cells ml-J (triangles), DNR incubation concentration: 3 /xM, 
cell density: 7.4.104 cells ml- i (circles). Both the y-axis and the x-axis 
were normalized with respect to differences in cell density (see text for 
additional details). The y-axis shows the passive fflux rate as calculated 
from the primary data (unit: counts per second (cps) per second). 
with a previous report [13]. The cellular quenching factor 
in the minus verapamil case, q-vp, was determined from 
the ratio of the initial fluorescence intensity and the final 
fluorescence intensity in the minus-verapamil efflux curve. 
Assuming that the DNR fluorescence intensity just before 
addition of digitonin in the minus-verapamil case, 
F_d~g '- vp(t ~ ~), represents F l, q_ Vp was estimated as 
F_vp(t  = 0) 
= 0.24 
q-vP= F dig_Vp(t ''~ ~) 
Under the assumption that in both the minus- and plus- 
verapamil case, the cells were loaded with the same amount 
of drug, F_dig '- vp(t ~ ~) also represents F l in the plus- 
verapamil case: 
F+vp( t = 0) 
=0.19  
q+vp = F_dig._vp(t ~ ~) 
These results are consistent with values reported previ- 
ously [22]. 
3.3. Drug effiux rates 
As described by Eq. (3), the rate at which the DNR 
fluorescence intensity increases hould be proportional to 
the DNR efflux rate. We began by analyzing the kinetics 
of the passive (i.e., the verapamil insensitive) DNR flux. 
Fig. 2 shows the slopes of plus-verapamil curves of three 
different experiments, plotted against the normalized (F~q 
- F+vp(t)) /(1 - q+vp). We refer to the axes as 'normal- 
ized axis' after correction for differences in cell density: 
both the y-axis and the x-axis depend on the cell density, 
the y-axes since the measured efflux rate depends on the 
number of cells present and the x-axis since the apparent 
distribution volume depends on the number of cells pre- 
sent. 
Each curve shows a deviation from linearity (i.e., to- 
wards higher slopes) at higher values of the normalized 
(F~q- F+vp(t))/(1 -q+vp)  (or at the start of DNR ef- 
flux) when compared to the other curves at the same 
normalized (F~q - F+ vp(t))/(1 - q+ vp). Part of this devi- 
ation may be due to a change of the apparent distribution 
volume with the intracellular free drug concentration. An 
increase of the apparent distribution volume may arise 
when during DNR efflux, the cellular binding sites change 
from a saturated to a non-saturated state. This increase of 
the apparent distribution volume during the first phase of 
DNR effiux may have led to the rapid decrease of the rate 
of change of the intracellular free DNR concentration 
during this phase. We have indications that saturation of 
cellular binding sites occurs at approx. 10/zM free cytoso- 
lic DNR concentration. Therefore, this effect may be ex- 
pected in the high-incubation concentration experiments 
(triangles and squares) but not in the low-incubation con- 
centration experiments (circles). The effect of a change of 
the apparent distribution volume during the first phase of 
effiux is taken into account in the mathematical nalysis in 
Eq. (4). We hypothesized that the remaining part of the 
deviation was due to a small percentage of damaged cells 
(in which the plasma membrane cannot control drug efflux 
anymore) or due to interference of a de-quenching signal 
from DNR multimers attached to the plasma membrane 
with a high fluorescence quenching [22]: in another study 
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Fig. 3. The slopes of the plus-verapamil (open squares) and minus- 
verapamil (closed squares) curves representing the drug efflux rate plot- 
ted against the normalized (Feq - F+ vp(t))/(l - q+ vp) using q+vp = 
0.19 and q-vp =0.24 for a representative experiment. Experimental 
parameters: plus-verapamil DNR incubation concentration: 15 /~M, mi- 
nus-verapamil DNR incubation concentration: 25 /xM, cell density: 3.7. 
104 cells ml -j . The y-axis hows the drug efflux rate as calculated from 
the primary data (unit: cps per second) expressed per 1 • 106 cells. The 
normalization f the x-axis of Fig. 2 was used for the x-axis of this figure 
(see text for additional details). 
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[23], we found more evidence for adsorbed DNR by 
fluorescence resonance nergy transfer measurements, us- 
ing a fluorescent plasma membrane probe. Within this 
hypothesis, the effect of the disturbance on the initial DNR 
fluorescence intensity is minimal, but it can produce errors 
in the estimate of/ :1,  the DNR fluorescence intensity if all 
intracellular DNR were free in solution. This could poten- 
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Fig. 4. (a, top) The slope of the minus-verapamil curve minus the slope of 
the plus-verapamil curve ( -A (d(F~q-  F+vp(t))/dt)) plotted against 
the normalized (Feq-  F+vp(t))/(1-q+vp) (which is related to the 
intracellular f ee drug concentration (see text for details)) for a represen- 
tative experiment. Experimental parameters: plus-verapamil DNR incuba- 
tion concentration: 15 /zM, minus-verapamil DNR incubation concentra- 
tion: 25 /xM, cell density: 3.7.104 cells ml -t . Both the y-axis and the 
x-axis were normalized to 1- 10 6 cells. (b, bottom) P-gp mediated DNR 
efflux rate, Vp.gp, plotted against the intracellular free DNR concentra- 
tion, C i, for three different experiments. Experimental parameters: plus- 
verapamil DNR incubation concentration: 15 ~M, minus-verapamil DNR 
incubation concentration: 25 /xM, cell density: 3.7.104 cells m1-1 
(squares), plus-verapamil DNR incubation concentration: 15 p~M, minus- 
verapamil DNR incubation concentration: 25 p,M, cell density: 7.4. l04 
cells m1-1 (triangles), plus-verapamil DNR incubation concentration: 3 
/xM, minus-verapamil DNR incubation concentration: 10 p,M, cell den- 
sity: 7.4.104 cells ml-1 (circles). The y-axis was calibrated using Eq. 
(6), the x-axis using Eq. (4). The common part of the three curves 
suggests a certain invariance towards the varied experimental p rameters. 
The deviation towards lower pump rates at higher intracellular DNR 
concentrations i dicates saturation fP-gp. 
tially lead to a systematic error in q ± Vp. However, since 
the calculated values for q-vp and q+vp are in the same 
range as reported previously [22], the error in F 1 is likely 
to be small. Since, within this hypothesis, this remaining 
part of the deviation is not specifically related to the drug 
effiux process, we deleted this part from the data set. From 
the non-overlapping part of the curve representing the 
experiment carried out at the low-incubation concentration 
(circles), we estimate that at 60 s after the start of drug 
efflux, most of the remaining part of the deviation does not 
contribute to the relevant signal anymore. We therefore 
deleted this part of each data set and used the remaining 
data for further calculations. 
In Fig. 3 the slopes of the plus- and minus-verapamil 
curves (as shown in Fig. 1) of a representative experiment 
are plotted against the normalized (Feq-  F± vp(t))/(1 - 
q ± Vp). Since each curve contains values of the slope at 
slightly different values of the normalized (Feq-  
F±vp(t))/(1- q±vp), the difference curve (slope of the 
minus-verapamil curve minus slope of the plus-verapamil 
curve as a function of the normalized (Feq -Fvp(t))/(1 
-q -vp) )  cannot be calculated directly. Therefore, the 
plus-verapamil curve was interpolated with a fifth order 
polynomial and this polynomial was used to calculate the 
slope of the plus-verapamil curve at the normalized (F~q -
F-vp(t))/(1 - q-Vp) values of the minus-verapamil curve. 
According to Eq. (1), (Feq-  F_vp(t))/(1- q-vp)  is 
related to the free drug concentration difference across the 
plasma membrane, C i ( t ) -  Co(t). In Fig. 4a the resulting 
difference curve of Fig. 3 is plotted. It shows that the 
pump rate is a saturable function of the intracellular free 
drug concentration. 
In Fig. 4b we calibrated and refined the results plotted 
in Fig. 4a with Eq. (4) for the three experiments described. 
The results of this calculation show a common part, which 
suggests an invariance (to some extent) towards certain 
experimental parameters. The deviation towards lower 
pump rates at higher intracellular DNR concentrations 
indicates saturation of the active pump. 
If the active component of DNR transport is described 
by a Michaelis-Menten type process, it follows from Fig. 
4b that the free cytosolic DNR concentration at Vmax/2 is 
1 /xM and Vma x is 3 pmol s -~ (10 6 cells) -~. The experi- 
ment carried out at the lower incubation concentrations did 
not show saturation to the same extent as the experiments 
performed at the higher incubation concentrations. This 
suggests that at this incubation concentration, in this cell 
line, complete saturation of P-gp has not occurred yet. 
4. Discussion 
In this article we described a method to determine K M 
and Vma x values for P-gp mediated DNR transport in a 
dynamic way, making use of the change of the DNR 
fluorescence intensity during DNR efflux from intact cells. 
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The method is based on the following principles. The 
internal substrate is divided between a bound and a free 
form, which are in rapid equilibrium. The measured fluo- 
rescence intensity is proportional to the total free substrate, 
both inside and outside the cell, the bound form being 
quenched. Because of the rapid equilibration of DNA 
binding, intracellular DNR behaves as a single pool, sub- 
ject to intermediate fluorescence intensity quenching. The 
rate of change of the fluorescence intensity during drug 
efflux should reveal the rate of drug export at various 
intracellular drug concentrations and should allow one to 
relate the pumping rate to the drug concentration. In 
essence, we measured the quenching factor and derived for 
each time point the drug export rate from the rate of 
change of the fluorescence intensity. Using a calibration 
curve determined under equilibrium conditions, we calcu- 
lated the intracellular free drug concentration (thermody- 
namic activity) at each time point from the amount of drug 
that is still in the cells. We then related the time varying 
export rate to the time varying intracellular free drug 
concentration. 
Because drug pumping is active transport and because 
the extracellular volume is much larger than the intra- 
cellular volume (so the extracellular drug concentration 
remains low), the extracellular drug will not influence the 
pumping rate. 
The kinetic parameters obtained are similar to values 
reported previously, using a flow-through system [8]. In 
that study, the passive influx was measured after a rapid 
inhibition of P-gp mediated DNR efflux in steady state 
(and leaving the intracellular drug concentration i tact for 
a while). The method presented in this article does not 
require the specialized set-up of a flow-through system, 
but uses only fluorometry. This method may be applied to 
rapidly screen toxic compounds for kinetic properties of 
drug resistance. 
For simplicity, this paper has been formulated in the 
sense that P-gp pumps from the cytosol. It has been 
suggested that P-gp pumps directly from the membrane, 
preventing any drug from entering the cytosol [2,24]. In 
the cells used in this paper, drug fluorescence was ob- 
served in the cytoplasm and in the nucleus by fluorescence 
microscopy. The fluorescence intensity quenching of the 
drug is due to its binding to DNA (fluorescence intensity 
quenching upon addition of digitonin is DNase I sensitive; 
data not shown). Virtually all of the drug effluxing from 
the cells in the experiments presented in this paper, ulti- 
mately derives from the drug bound to intracellular DNA. 
Most likely, therefore, the effluxing drug has gone through 
the cytosol. Our results do not specify whether or not the 
active extrusion of the drug from the cell is due to 
pumping from the cytosol or pumping from the membrane. 
However, if pumping was from the membrane, the mem- 
brane concentration of the drug should respond effectively 
to changes in the cytosol and DNA. The drug pump in our 
KB8-5 cells cannot be a 100% effective vacuum cleaner. 
Independent of the mechanism, our results demonstrate 
that drug pumping exhibits saturable kinetics in terms of 
the concentration f the bulk of intracellular drug. 
The Kr~ for P-gp mediated DNR transport lies pre- 
dominantly above drug plasma concentrations [25]. There- 
fore the relative contribution of a given amount of P-gp to 
the total drug transport rate (i.e., the ratio of the active 
pump rate and the total (passive and active) efflux rate) is 
large, when compared to a situation in which the drug 
plasma concentrations would lie above the K M at a given 
pumping rate. This implies that toxic compounds or 
metabolites for which the drug plasma concentrations are 
above the K M (at the same Vmax/K M, such that at much 
lower substrate concentrations the pumping rate is the 
same at equal substrate concentrations), may be preferable 
anticancer drugs in cases in which P-gp plays an important 
role in drug resistance. 
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Appendix A 
The objective of this theoretical description of DNR 
transport across the plasma membrane is to calculate the 
rate of P-gp mediated transport as a function of the intra- 
cellular free drug concentration. The analysis is divided in 
four parts. In the first part, the kinetic model is defined and 
the assumptions are outlined. In the second part, the free 
drug concentration difference across the plasma membrane 
as a function of time is calculated from experimental data. 
In the third part, the rate of P-gp mediated transport is 
calculated as a function of the free drug concentration 
difference across the plasma membrane from experimental 
data and the results from the second part. In the fourth 
part, the intracellular f ee drug concentration is calculated 
from the total cellular DNR content (which is calculated 
from experimental data) and an experimentally determined 
relation between the total cellular drug content and the 
intracellular f ee drug concentration: the apparent distribu- 
tion volume. Combination of these results yields the rate of 
P-gp mediated transport as a function of the free intra- 
cellular drug concentration. 
A. 1. Kinet ic  model  and  assumpt ions 
DNR transport across the plasma membrane will be 
described with a three compartment model: the extracellu- 
lar space, a cellular space (e.g. cytosol) and a compartment 
which equilibrates rapidly with the cellular space, but 
quenches the DNR fluorescence intensity. Drug transport 
is described as the sum of a passive component (diffusion) 
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and active component (P-gp mediated). P-gp is assumed to 
pump between the extracellular nd the cellular space. 
The rate of passive free drug transport across the mem- 
brane (referred to as the leak rate), Jl(Ci(t), Co(t)) (mol 
s -1 (10 6 cells)-l), will in general dependent on both the 
intracellular and extracellular f ee drug concentration: 
J i(Ci(t) ,Co(t)) =f l  (Ci(t) ,Co(t))  (A1) 
in which Ci(t) (mol 1-1) and Co(t) (mol 1-1) represent the 
intracellular and extracellular f ee drug concentration, re- 
spectively and the form of fl(Ci(t),Co(t)) describes the 
explicit dependence. The active component of free drug 
transport is assumed to be independent of the extracellular 
drug concentration. The rate of active transport (referred to 
as the pump rate), Jp(Ci(t)) (mol s 1 (10 6 cells)-1), can 
be written as: 
Jp(Ci(t)) =f2(Ci ( t ) )  (A2) 
in which the form of the function f2(Ci(t)) depends on the 
specific model used to describe DNR transport across the 
plasma membrane. In the main text, the data are analyzed 
in the context of a Michaelis-Menten model. 
Most likely the main depot of intracellular quenched 
DNR is cellular DNA. Because of the rapid equilibrium 
between intracellular f ee DNR and DNA bound DNR, we 
will consider a single pool of cellular DNR with intermedi- 
ate quenching. 
A.2. Calculation of Ci(t) - Co(t) from experimental data 
During drug efflux, the cellular DNR fluorescence in- 
tensity follows the dashed line and the cellular DNR 
fluorescence intensity plus medium DNR fluorescence 
intensity is represented by the experimentally obtained 
solid line in Scheme 1. The upper theoretical level, F 1 
(counts per s, cps), would be obtained if all the DNR were 
free in the extracellular solution after efflux. F 1 (cps) 
exceeds the fluorescence intensity obtained after permeabi- 
lization of the plasma membrane by digitonin and equili- 
bration of DNR across the plasma membrane, Feq (cps), 
since some of the DNR will remain intercalated in DNA 
and its fluorescence intensity will be quenched. We define 
the cellular quenching factor, q ± Vp, as 
F± Vp(t = 0) 
q ± Vp F, (A3) 
in which F± vp(t  = 0) (cps)  is the cellular DNR fluores- 
cence intensity at the start point of effiux in the absence or 
presence of verapamil. 
At time zero, all DNR resides inside the cells. The 
fraction of intracellular DNR at time t, x(t), is defined as: 
Qi ( t )  
x ( t )  (A4)  
a i (  t = 0) 
in which Qi(t) (tool) is the cellular DNR content at time t. 
F1(1 
T . . . . . . . . . . . . . . . .  ~ .._ X,,qq F1 
0 0 F " . . . . . . . . . .  . . . . . . . . . . . .  
Scheme 1. Schematic representation f factors determining the daunoru- 
bicin (DNR) fluorescence intensity during efflux of cellular DNR. The 
fluorescence intensity of cellular DNR is represented by a dashed line and 
the (measured) total fluorescence intensity (of cells plus medium) by a 
solid line. At time t the total fluorescence, F± ~p(t), contains a contribu- 
tion of the cellular DNR fluorescence intensity, x(t)q± vpFj, and of the 
medium DNR fluorescence intensity, (1 - x(t))F t, and the signal would 
increase by x(t)(1-q+ vp)Fi during complete efflux. Feq refers to the 
fluorescence intensity obtained after plasma membrane permeabilization, 
x(t) represents the fraction (relative to t = 0) of intracellular DNR and 
q± vp is the cellular quenching factor, due to DNA intercalation of DNR. 
At t = 0, x(t) equals 1 and the fluorescence intensity of 
the intracellular DNR is quenched to q ± Vp F1. At time t, 
the fluorescence intensity of the intracellular DNR equals 
x(t)q ± vpF1 and the fluorescence intensity of the extracel- 
lular fraction, (1 - x(t)), equals (1 - x(t))F v 
The intracellular f ee drug concentration, Ci(t), can be 
written as: 
eF 1 
Ci ( t  ) Vcells(Ci(t) x ( t )  (m5)  
in which e (mol cps -1 ) is a constant hat relates the 
medium DNR fluorescence to the amount of DNR in the 
medium, as can be determined by adding a known DNR 
concentration to the incubation mixture. V~eus(Ci(t)) (1) is 
the apparent distribution volume for DNR of the cells, 
defined as 
Qi ( t )  
Vcen~(Ci(t)) Ci(t ) (A6) 
The extracellular f ee drug concentration, Co(t), can be 
written as: 
Co(t ) = V--~t (1 - x(t))  (A7) 
in which Vou t (1) represents the extracellular or efflux 
medium volume and is related to the apparent total vol- 
ume, Vtot(Ci(t)) (1), by: Vtot(Ci(t))= Vceu~(Ci(t))+ Vou t. 
Since the apparent distribution volume varies with the 
intracellular free drug concentration, the apparent otal 
volume also depends on Ci(t). Combination of Eqs. (A5) 
and (A7) yields an expression for the free drug concentra- 
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tion difference across the plasma membrane as a function 
of the fraction of intracellular DNR: 
Ci ( t ) -Co( t )= eFl ~ Vc~lls(Ci(t) Vt°t(Ci(t)) 1) (A8) 
Experimentally, we can determine the difference be- 
tween the measured DNR fluorescence intensity after t s 
of effiux, F+ Vp(t) and Feq, the DNR fluorescence inten- 
sity after plasma membrane permeabilization with digi- 
tonin, when Ci(t) - Co(t) = 0. From Scheme 1 it follows 
that 
Feq = FI - Xeq FI( --q+ Vp) 
F+ vp(t) = F, - x( t)rl(1 - q+ vp) 
(A9) 
in which Xeq is defined as the intracellular f action when 
C i ( t ) -  Co(t)= 0. Substitution of this condition in Eq. 
(A8) leads to 
Wcells( Ci,eq ) 
Xeq gtot(Ci,eq ) (A10) 
Combination of Eqs. (A9) and (A10) yields: 
x(t) 
(All) 
in which Vcells(fi,eq)/Vtot(fi,eq) represents the fraction of 
the total cuvette volume accessible to the intracellular 
DNR, comprising the extra virtual volume arising from 
DNA binding. Since at relatively low cell densities 
Vcells(fi,eq)//gtot(Ci,eq)<<l, Eq. (A9) shows that the error 
introduced by using F~q instead of F 1 will be small when 
compared to other (experimental) errors. 
Eq. (A11) yields x(t) in terms of F~q - F+ vp(t) which 
can subsequently be substituted in Eq. (A8) to yield: 
Ci(t ) - Co(t ) 
Feq - F+_ vp(t ) ~ Vtot(Ci(t)) 
1 -- q+ Vp VoutVcel,s(Ci(t)) 
~'Fl ( Vcells(Ci,eq) Vtot(Ci(t)) ) 
+ Vout Vc~tls(Ci(t) ) Vtot(Cixq) 1 (g12) 
If the apparent distribution volume were independent of 
the in t race l lu la r  free drug concent ra t ion ,  
Vcelts(Ci,eq)/Vcells(Ci(t)) and Vtot(fi.eq)/Vtot(fi(t)) would 
both equal 1 and the second term in Eq. (A12) would 
vanish. Since neither Vc,lls(Ci(t)) nor Vtot(Ci(t)) are known 
explicitly, it is not possible to calculate Ci(t) -  Co(t ) 
explicitly. However, since the free drug concentration dif- 
ference across the plasma membrane depends on the activ- 
ity of the pump only through Feq - F+ vp(t), it is possible 
to compare C i ( t ) -  Co(t) in the presence and absence of 
pumping: when we wish to compare drug effiux rates in 
the presence and the absence of pumping at the same 
C i ( t ) -  Co(t), we can compare them also at the same 
Feq - F+ vp(t) 
A.3. Deriving leak and pump kinetics from drug efflux 
curves 
According to the kinetic model defined in the first part 
of this appendix, the total DNR efflux rate, J(Ci(t), Co(t)) 
(mol s -l (10 6 cells-l)), can be expressed as 
J(Ci(t),Co(t)) = Jl(Ci(t),Co(t)) + Jo(Ci(t),Co(t)) 
(A13) 
in which Jl(Ci(t),Co(t)) represents the leak rate and 
Jp(Ci(t),Co(t)) the pump rate. The DNR efflux rate in the 
presence of verapamil, when P-gp mediated DNR efflux is 
completely inhibited, J+vp(Ci(t),Co(t)), can be written as 
g+vp(Ci(t) ,Co(t)) = g,(c i ( t)  ,Co(t)) CA14) 
As a consequence, the pump rate can be obtained by 
subtracting the effiux rate in the presence of verapamil and 
in the absence of verapamil, provided that the two effiux 
rates were measured at the same values of Ci(t) and Co(t): 
Jp(Ci(t) ,Co(t)) 
= J(Ci(t)  ,Co(t)) - J l(Ci(t) ,Co(t)) 
=g_vp(Ci(t),Co(t)) -g .  vp(Ci(t),Co(t)) (A15) 
When the cells at the same cell density are loaded with 
the same amount of drug and the extracellular concentra- 
tions are equal in both the plus- and minus-verapamil case 
it can be shown that the concentration difference across the 
plasma membrane is equal in both cases. Consequently, 
efflux rates at the same extracellular concentration or the 
same fluorescence intensity may be subtracted: 
Jp(F vp( t ) )=g vp(e_vp( t ) ) -  g+vp(F+vv(t)) 
(A16) 
or within the assumption of loading with the same amount: 
Jp(Feq-F vp(t))=J-vp(Feq- F_vp(t)) 
- J+vp(Feq-  F+vp(t))  (a17) 
Since the fluorescence intensity difference, Feq - F+ vp(t), 
is related to Ci(t) - Co(t) (Eq. (A12)), a plot of Jl(Feq - 
F+vp(t)) versus Feq- F+vp(t) should reveal the depen- 
dence of passive drug effiux on C~(t) - Co(t). Similarly, a 
plot of Jp(Feq-F_vp(t)) versus Feq-F_vp(t )  should 
reveal the dependence of the pump rate on C+(t) - Co(t). 
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The rate of change of the DNR fluorescence intensity is 
related to the transport rate, J(Ci(t),Co(t)), through: 
J+  vp(C i ( t )  ,Co( t ) )  
dQo(t ) d 
-- d----~ dt (eF l (1 -x ( t ) ) )  
e d 
- 1 -q+vp dt(F+vp(t ) )  (g18) 
Together with Eq. (A12), this relation allows us to calcu- 
late how the transport rate (both in the absence and 
presence of verapamil) varies with the free drug concentra- 
tion difference across the plasma membrane. 
A.4. Calculation of the intracellular free drug concentra- 
tion Ci(t) 
The intracellular f ee drug concentration is determined 
from the total cellular DNR content, ai(t). From Eq. (A5), 
Qi(t) can be written as: 
( Feq-F+vp(t) Vcells(Ci,eq) ) 
Qi( t) = eFlX( t) = eF, -F~l(~-q~vp ) + gtot(Ci,eq ) 
Feq - F+ Vp(t) 
= e (A19)  
1 - q+vp 
if V~ells(Ci,eq)/Vtot(Ci,eq) s assumed to be much smaller 
than unity. The intracellular free drug concentration is 
determined with the experimental ly determined relation 
between total cellular drug content and intracellular free 
drug concentration: the apparent distribution volume (un- 
published results): 
Q i ( t )  
Ca(t) Vcells ( C i ( t ) )  (A20) 
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